# FASENRA Patient Injection Record

Fasenra™ (benralizumab) Subcutaneous injection 30 mg | AstraZeneca Access 360™

**Use this log to record injection history for your FASENRA patient**

| | | | |
|---|---|---|---|
| Patient name: | Date of birth: | Insurance ID: | |
| Prescriber/Physician name: | Preferred phone number: | Other phone number: | |
| Specialty pharmacy provider (SPP): | SPP phone number: | PA approval date: | PA expiration date: |

| | Injection due date | Actual injection date | Injection site(s) | Comments/observations | Lot number | Expiration | Order shipped | Order arrived | SPP contact name | Refill needed (Y/N) | Initials |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | **STARTING DOSES** (Once every 4 weeks for the first 3 doses) | | | | | | | | | | |
| 1 | | | | | | | | | | | |
| 2 | | | | | | | | | | | |
| 3 | | | | | | | | | | | |
| | **MAINTENANCE DOSES** (Once every 8 weeks) | | | | | | | | | | |
| 4 | | | | | | | | | | | |
| 5 | | | | | | | | | | | |
| 6 | | | | | | | | | | | |
| 7 | | | | | | | | | | | |
| 8 | | | | | | | | | | | |

## INDICATION

FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

- FASENRA is not indicated for treatment of other eosinophilic conditions
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus

## DOSAGE AND ADMINISTRATION

**FASENRA comes in a single-dose, prefilled syringe for administration.**

- The recommended dose of FASENRA is 30 mg administered **once every 4 weeks for the first 3 doses,** and then **once every 8 weeks thereafter** by subcutaneous injection into the upper arm, thigh, or abdomen

**Please see additional Important Safety Information and Dosing Considerations on other side and accompanying full Prescribing Information, including Patient Information.**

Fasenra™ (benralizumab) Subcutaneous injection 30 mg | AstraZeneca Access 360™

# IMPORTANT SAFETY INFORMATION

## CONTRAINDICATIONS

Known hypersensitivity to benralizumab or excipients.

## WARNINGS AND PRECAUTIONS

### Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.

### Acute Asthma Symptoms or Deteriorating Disease

FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

### Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

### Parasitic (Helminth) Infection

It is unknown if FASENRA will influence a patient's response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.

## ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 5%) include headache and pharyngitis.

Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo.

## USE IN SPECIFIC POPULATIONS

The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

# ADDITIONAL DOSING CONSIDERATIONS

FASENRA is for subcutaneous use only.

FASENRA should be administered by a healthcare professional. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended. Prior to administration, warm FASENRA by leaving carton at room temperature for about 30 minutes. Administer FASENRA within 24 hours or discard into sharps container.[1]

**Please see accompanying full Prescribing Information, including Patient Information.**

***You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.***

***For more information, please contact AstraZeneca Access 360™ at 1-833-360-HELP, Monday through Friday, 8 AM to 8 PM ET.***

**1-833-360-HELP** (1-833-360-4357)

**1-833-FAX-A360** (1-833-329-2360)

**www.FasenraResources.com**

**Access360@AstraZeneca.com**

**One MedImmune Way,** Gaithersburg, MD 20878

**Reference: 1.** FASENRA [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2017.



AstraZeneca